- Home
- BHR vs KLRS Comparison
BHR vs KLRS Comparison
Compare BHR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHR
- KLRS
- Stock Information
- Founded
- BHR 2013
- KLRS 2019
- Country
- BHR United States
- KLRS United States
- Employees
- BHR N/A
- KLRS N/A
- Industry
- BHR Real Estate Investment Trusts
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHR Real Estate
- KLRS Health Care
- Exchange
- BHR Nasdaq
- KLRS Nasdaq
- Market Cap
- BHR 131.4M
- KLRS 129.0M
- IPO Year
- BHR N/A
- KLRS N/A
- Fundamental
- Price
- BHR $2.53
- KLRS $2.90
- Analyst Decision
- BHR
- KLRS Buy
- Analyst Count
- BHR 0
- KLRS 1
- Target Price
- BHR N/A
- KLRS N/A
- AVG Volume (30 Days)
- BHR 331.6K
- KLRS 51.7K
- Earning Date
- BHR 07-30-2025
- KLRS 05-14-2025
- Dividend Yield
- BHR 7.87%
- KLRS N/A
- EPS Growth
- BHR N/A
- KLRS N/A
- EPS
- BHR N/A
- KLRS N/A
- Revenue
- BHR $723,586,000.00
- KLRS N/A
- Revenue This Year
- BHR N/A
- KLRS N/A
- Revenue Next Year
- BHR $2.32
- KLRS N/A
- P/E Ratio
- BHR N/A
- KLRS N/A
- Revenue Growth
- BHR N/A
- KLRS N/A
- 52 Week Low
- BHR $1.80
- KLRS $2.65
- 52 Week High
- BHR $3.95
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- BHR 64.48
- KLRS N/A
- Support Level
- BHR $2.24
- KLRS N/A
- Resistance Level
- BHR $2.59
- KLRS N/A
- Average True Range (ATR)
- BHR 0.16
- KLRS 0.00
- MACD
- BHR 0.03
- KLRS 0.00
- Stochastic Oscillator
- BHR 90.48
- KLRS 0.00
About BHR Braemar Hotels & Resorts Inc.
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.